Editorial: Breast cancer and the risk of osteoporotic fracture: A paradox

Journal of Clinical Endocrinology and Metabolism

Volumn 92, Issue 1, 2007, Pages 42-43

  Eastell, Richard ^a,b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b NORTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANASTROZOLE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; IBANDRONIC ACID; LETROZOLE; PAMIDRONIC ACID; PLACEBO; RALOXIFENE; RISEDRONIC ACID; TAMOXIFEN; ZOLEDRONIC ACID;

ALCOHOL CONSUMPTION; BONE DENSITY; BONE DISEASE; BONE TURNOVER; BREAST CANCER; CLINICAL TRIAL; EDITORIAL; FRACTURE; FRAGILITY FRACTURE; HUMAN; LUMBAR SPINE; MENARCHE; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; RIB FRACTURE; RISK FACTOR; SIDE EFFECT; SMOKING HABIT; BREAST TUMOR; FEMALE; NOTE; POSTMENOPAUSE OSTEOPOROSIS;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; FRACTURES, BONE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; RISK FACTORS;

EID: 33846181034     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2006-2437     Document Type: Editorial

References (20)

1. Greenspan SL, Bhattacharya RK, Sereika SM, Brufsky A, Vogel VG 2007 Prevention of bone loss in survivors of breast cancer: a randomized, double-blind, placebo-controlled clinical trial. J Clin Endocrinol Metab 92:131-136
2. Delmas PD, Balena R, Confravreux E, Hardouin C, Hardy P, Bremond A 1997 Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. J Clin Oncol 15:955-962
3. Saarto T, Blomqvist C, Valimaki M, Makela P, Sarna S, Elomaa I 1997 Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients. J Clin Oncol 15:1341-1347
4. Powles TJ, Mccloskey E, Paterson AH, Ashley S, Tidy VA, Nevantaus A, Rosenqvist K, Kanis J 1998 Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer. J Natl Cancer Inst 90:704-708
5. Vehmanen L, Saarto T, Elomaa I, Makela P, Valimaki M, Blomqvist C 2001 Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatment. Eur J Cancer 37(18):2373-2378
6. Vehmanen L, Saarto T, Risteli J, Risteli L, Blomqvist C, Elomaa I 2004 Short-term intermittent intravenous clodronate in the prevention of bone loss related to chemotherapy-induced ovarian failure. Breast Cancer Res Treat 87:181-188
7. El-Hajj Fuleihan G, Salamoun M, Mourad YA, Salamoun M, Mourad YA, Chehal A, Salem Z, Mahfoud Z, Shamseddine A 2005 Pamidronate in the prevention of chemotherapy-induced bone loss in premenopausal women with breast cancer: a randomized controlled trial. J Clin Endocrinol Metab 90:3209-3214
8. Shapiro CL, Manola J, Leboff M 2001 Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol 19:3306-3311
9. Chen Z, Maricic M, Bassford TL, Pettinger M, Ritenbaugh C, Lopez AM, Barad DH, Gass M, Leboff MS 2005 Fracture risk among breast cancer survivors: results from the Women's Health Initiative Observational Study. Arch Intern Med 165:552-558
10. Pierce SM, Recht A, Lingos TI, Abner A, Vicini F, Silver B, Herzog A, Harris JR 1992 Long-term radiation complications following conservative surgery (CS) and radiation therapy (RT) in patients with early stage breast cancer. Int J Radiat Oncol Biol Phys 23:915-923
11. Chen Z, Maricic M, Pettinger M, Ritenbaugh C, Lopez AM, Barad DH, Gass M, Leboff MS, Bassford TL 2005 Osteoporosis and rate of bone loss among postmenopausal survivors of breast cancer. Cancer 104:1520-1530
12. Eastell R, Hannon R 2005 Long-term effects of aromatase inhibitors on bone. J Steroid Biochem Mol Biol 95:151-154
13. Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, Mulvihill JJ 1989 Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 81:1879-1886
14. Eastell R 2005 Role of oestrogen in the regulation of bone turnover at the menarche. J Endocrinol 185:223-234
15. Cauley JA, Lucas FL, Kuller LH, Vogt MT, Browner WS, Cummings SR 1996 Bone mineral density and risk of breast cancer in older women: the Study of Osteoporotic Fractures. Study of Osteoporotic Fractures Research Group. JAMA 276:1404-1408
16. Kerlikowske K, Shepherd J, Creasman J, Tice JA, Ziv E, Cummings SR 2005 Are breast density and bone mineral density independent risk factors for breast cancer? J Natl Cancer Inst 97:368-374
17. Johnell O, Kanis JA, Oden A, Johansson H, De Laet C, Delmas P, Eisman JA, Fujiwara S, Kroger H, Mellstrom D, Meunier PJ, Melton III LJ, O'Neill T, Pols H, Reeve J, Silman A, Tenenhouse A 2005 Predictive value of BMD for hip and other fractures. J Bone Miner Res 20:1185-1194
18. Hillner BE, Ingle JN, Chlebowski RT, Gralow J, Yee GC, Janjan NA, Cauley JA, Blumenstein BA, Albain KS, Lipton A, Brown S; American Society of Clinical Oncology 2003 American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21:4042-4057
19. Brufsky A 2006 Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update. Semin Oncol 33(2 Suppl 7):S13-S17
20. Eastell R, Hannon RA, Cuzick J, Dowsett M, Clack G, Adams JE; ATAC Trialists' group 2006 Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the anastrozole, tamoxifen, alone or in combination (ATAC) trial (18233230). J Bone Miner Res 21:1215-1223